Neil F. McFarlane - 16 May 2024 Form 4 Insider Report for COLLEGIUM PHARMACEUTICAL, INC (COLL)

Reporting relationship: Director
Issuer ticker: COLL
Reported as of: 16 May 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 May 2024, 19:23:00 UTC
Prior SEC filing: 02 Feb 2024
Next SEC filing: 03 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Shirley R. Kuhlmann as Attorney-in-Fact for Neil F. McFarlane

Key filing fact

Neil F. McFarlane filed Form 4 for COLLEGIUM PHARMACEUTICAL, INC (COLL) on 16 May 2024.

Key facts

This page summarizes Neil F. McFarlane's Form 4 filing for COLLEGIUM PHARMACEUTICAL, INC (COLL).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 16 May 2024, 19:23.

Change

Previous filing in this sequence was filed on 02 Feb 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

COLL transaction

Common Stock

Award

Transaction value: $0
Shares: +7,693
Change %: +18%
Price: $0.000000
Shares after: 49,365
Date: 16 May 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.